After a 5-year repeat PhIII sojourn, Lundbeck and Otsuka say they're finally ready to pursue OK to use Rexulti against Alzheimer's agitation
Five years after Lundbeck and their longtime collaborators at Otsuka turned up a mixed set of Phase III data for Rexulti as a treatment for Alzheimer’s dementia-related agitation, they’ve come through with a new pivotal trial success they believe will finally put them on the road to an approval at the FDA. And if they’re right, some analysts believe they’re a short step away from adding more than $500 million in annual sales for the drug, already approved in depression and schizophrenia.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,300+ biopharma pros reading Endpoints daily — and it's free.